Case Report Sepsis Due To Pseudomonas Aeruginosa
Case Report Sepsis Due To Pseudomonas Aeruginosa
Presenter :
dr. Hasnawati Tahir
dr. Zulvinah Santy Arsyad,M.Kes
dr. Nurlianti
Supervisor
Prof. dr. Mochammad Hatta, Ph.D., Sp.M.K, SubSp. Bakt. (K)
dr. Firdaus Hamid, Ph.D., Sp.MK., SubSp. Bakt (K)
dr. Rizalinda Sjahril, Ph. D., M. Sp. M.K., SubSp. Vir. (K)
Tanggal lahir :31 Desember 1967 Ruangan : Rawat Inap Sandeq 403
Kateter urine
Tanggal 19 Oktober 2023 Hari ke-2
Hasil Laboratorium
1000x 1000x
Mikroorganisme : Basil Gram Negatif Mikroorganisme : Basil Gram Negatif
Follow Up 21 Oktober 2023
Hari Kedua Darah dari lengan kiri diinokulasi di Blood agar
(mikroaerofilik )
Karakteristik Hasil
Koloni
Bentuk Bulat
Ukuran Sedang
Tepi Rata
Permukaan Halus
Kekeruhan Keruh
Elevasi Cembung
Warna Putih keabuan
Sifat Hemolisisi Gamma
hemolisis
Mikroorganisme :
Basil Gram Negatif CMPH 3.2.1 Gram Stain
Follow Up Tanggal 21 Oktober 2023
Hari Kedua Darah dari kaki kanan
diinokulasi ke Blood Agar
Karakteristik Hasil
Koloni
Bentuk Bulat
Ukuran Sedang
Tepi Rata
Permukaan Halus
Elevasi Cembung
Kekeruhan Keruh
Warna Putih keabuan
Sifat Hemolisisi Gamma hemolisis
Mikroorganisme :
Basil Gram Negatif
Tanggal 21 Oktober 2023
Darah dari lengan kiri diinokulasi ke
Mac Conkey Agar ( Aerob)
Ceftriaxone : 21 mm : ( R )
Levofloxacin : 25 mm : ( S )
Hasil Maldi –TOF tangal 27 Oktober 2023
Assessment Syok Sepsis qsofa 1, Severe Syok Sepsis qsofa 1, Severe Syok Sepsis qsofa 1, Severe
neutropenia, AKI Induced neutropenia, AKI Induced neutropenia, AKI Induced
Chemotherapy, Chemotherapy Chemotherapy, Chemotherapy, Chemotherapy
induced Pansitopenia, Chemotherapy induced induced Pansitopenia,
Karsinoma Pansitopenia, Karsinoma Karsinoma Nasofaring
Nasofaring,Stadium IV Nasofaring Stadium IVB Stadium IVB (T3N1M1),
B(T3N1M1), Hiponatremia (T3N1M1), Hiponatremia Hiponatremia
sedang,Hipokalemia ringan sedang,Hipokalemia ringan sedang,Hipokalemia ringan
cultures
for optimal organism recovery.
Leber, Amy L., Clinical microbiology procedures handbook. Department of Laboratory Medicine, OHIO. 2016. 4th Edition
Pseudomonas aeruginosa
GENERAL INFORMATION
Pseudomonas aeruginosa is an
opportunistic pathogen that causes
several infections in human.
Mahon, Connie R., M. S. Mt, and Donald C. Lehman. Textbook of diagnostic microbiology. 2019
Proctor,L.et.al.Potential Therapeutic Targets for Combination Antibody Therapy against Pseudomonas aeruginosa Infections.2021
Taxonomy Pseudomonas aeruginosa
Domain : Bacteria
Phylum : Proteobacteria
Order : Pseudomonadales
Family : Pseudomonadaceae
Genus : Pseudomonas
Liao,C.et.al.Virulence Factors of Pseudomonas Aeruginosa and Antivirulence Strategies to Combat Its Drug Resistance.2022
PATHOGENESIS
Qin, S., Xiao, W., Zhou, C. et al. Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Sig Transduct Target Ther 7, 199 (2022)
Treatment
Pseudomonas aureginosa
Primary regimens:
• Levofloxacin
• Piperacillin-tazobactam
• Ceftazidime
• Cefepime
• Meropenem
• Ceftolozane-tazobactam
• Aztreonam
• Ciprofloxacin for severe igE -mediated beta -lactam allergy
• Levofloxacin
Zakhour, J;2022:Antimicrobial treatment of Pseudomonas aeruginosa severe sepsis. Antibiotics, 11(10), 1432 .
PPRA
PPRA
Reference
• Zakhour, J., Sharara, S. L., Hindy, J. R., Haddad, S. F., & Kanj, S.
S. (2022). Antimicrobial treatment of Pseudomonas aeruginosa
severe sepsis. Antibiotics, 11(10), 1432.
• PERMENKES No.28 Tahun 2021. Pedoman Penggunaan
Antibiotik
• Sanfor 2022
• PERMENKES No.8 Tahun 2015. Program Pengendalian
Resistensi Antimikrobadi RumhaSakit.
Thank you